Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Breast Cancer
100%
Radiation Therapy
100%
Radiotherapy
100%
Hormone Receptor
100%
Cellular Senescence
100%
Cyclin-dependent Kinase 4/6 Inhibitors
100%
Palbociclib
62%
P16INK4a
25%
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
25%
Caspase-8
25%
Cyclin-dependent Kinase 6 (CDK6)
25%
Mammary Carcinogenesis
25%
Senescent Cells
25%
Malignant Cells
12%
Tumor Microenvironment
12%
Tumor
12%
Senescence
12%
Beneficial Effects
12%
Tumor Model
12%
Tumor Growth
12%
7,12-dimethylbenz(a)anthracene
12%
Mouse Model
12%
MCF-7 Cells
12%
Detrimental Effects
12%
Overall Survival
12%
Oral Administration
12%
Adenocarcinoma
12%
Progression-free Survival
12%
Anticancer Effect
12%
Senescence-associated
12%
Breast Cancer Cell Lines
12%
MDA-MB-231 Cells
12%
Response to Treatment
12%
Human Breast Cancer
12%
β-Galactosidase (β-Gal)
12%
Mammary Carcinoma
12%
Mouse Breast Cancer
12%
Mammary Tumor
12%
In Vivo Depletion
12%
Proliferative Arrest
12%
Driving Model
12%
Triple-negative Breast Carcinoma
12%
Focal Irradiation
12%
Medroxyprogesterone Acetate
12%
Subcutaneous Implantation
12%
Dimerizer
12%
Bioactive Factors
12%
AP20187
12%
Differential Accumulation
12%
Human Hormones
12%
Immunobiologics
12%
Medicine and Dentistry
Breast Cancer
100%
Cellular Senescence
100%
Hormone Receptor
100%
Radiation Therapy
100%
Palbociclib
55%
Carcinogenesis
22%
Caspase 8
22%
Tumor
22%
Tumor Progression
11%
Secretion (Process)
11%
Tumor Microenvironment
11%
In Vitro
11%
Tumor Model
11%
Breast Cancer Cell Line
11%
Overall Survival
11%
Promoter Region
11%
Triple Negative Breast Cancer
11%
Adenocarcinoma
11%
7,12 Dimethylbenz[a]anthracene
11%
Oral Drug Administration
11%
Progression Free Survival
11%
Breast Carcinoma
11%
Dimethylbenz[a]anthracene
11%
Galactosidase
11%
Cyclin Dependent Kinase Inhibitor 2A
11%
Pharmacology, Toxicology and Pharmaceutical Science
Cyclin Dependent Kinase 4
100%
Breast Cancer
100%
Hormone Receptor
100%
Palbociclib
71%
Carcinogenesis
28%
Caspase 8
28%
Mouse Model
14%
7,12-Dimethylbenz(a)anthracene
14%
Cyclin Dependent Kinase Inhibitor 2A
14%
Dimethylbenz[a]anthracene
14%
Medroxyprogesterone Acetate
14%
Tumor Growth
14%
Tumor Model
14%
Overall Survival
14%
Triple Negative Breast Cancer
14%
Breast Carcinoma
14%
Tumor Microenvironment
14%
Galactosidase
14%
Progression Free Survival
14%
Adenocarcinoma
14%
Oral Administration
14%
Biochemistry, Genetics and Molecular Biology
Hormone Receptor
100%
Cyclin-Dependent Kinase 4
100%
Carcinogenesis
28%
Caspase 8
28%
Mouse Model
14%
Anticancer
14%
Cancer Cell
14%
Secretion (Process)
14%
Promoter Region
14%
Overall Survival
14%
Tumor Progression
14%
Progression Free Survival
14%
Medroxyprogesterone Acetate
14%
Galactosidase
14%
Cyclin Dependent Kinase Inhibitor 2A
14%